Effects of dexmedetomidine on performance of bispectral index as an indicator of loss of consciousness during propofol anesthesia

Dexmedetomidine influence on performance of bispectral index

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002376

Enrollment

Unknown

Registered

2012-07-21

Start date

2012-05-08

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

general anesthesia

Interventions

control group:intravenously infuse saline

DEX 0.5 ug/kg group:intravenously infuse DEX 0.5 ug/kg

DEX 1.0 ug/kg group:intravenously infuse DEX 1.0 ug/kg

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with ASA I or II and aged 25-60 yr, who were scheduled for general anesthesia.

Exclusion criteria

Exclusion criteria: body mass index >30 kg/m2, bradycardia, atrioventricular block, neurologic disorder and recent use of psychoactive medication, including alcohol.

Design outcomes

Primary

Measure	Time frame
bispectral index;	—

Secondary

Measure	Time frame
Observer’s Assessment of Alertness/Sedation scale;effect-site concentration of propofol;	—

Countries

China

Contacts

Public ContactDonghua Shao

sdonghua@yahoo.cn+86 13805281211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026